Tools
Tools
Burnett, A K, Russell, N, Hills, R K, Panoskaltsis, N, Khwaja, A, Hemmaway, C, Cahalin, P, Clark, R E and Milligan, D (2015) A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. ISSN 1476-5551.
Full text not available from this repository.Abstract
The development of new treatments for older patients with acute myeloid leukaemia (AML) is an active area, but has met with limited success. Sapacitabine is a novel orally administered nucleoside analogue that has shown encouraging activity in unrandomised early-stage trials. We randomised 143 untreated patients with AML or with high-risk myelodysplastic syndrome (>10% marrow blasts) between sapacitibine and low-dose ara-C (LDAC) in our 'Pick a Winner' trial design. At the planned interim analysis there was no difference between LDAC and sapacitibine in terms of remission rate (CR/CRi, 27% vs 16% hazard ratio (HR) 1.98(0.90-4.39) P=0.09), relapse-free survival (10% vs 14% at 2 years, HR 0.73(0.33-1.61) P=0.4) or overall survival (OS; 12% vs 11% at 2 years, HR 1.24(0.86-1.78) P=0.2). Sapacitibine was well tolerated, apart from more grade 3/4 diarrhoea. On the basis of these findings sapacitibine did not show sufficient evidence of benefit over LDAC for the trial to be continued.Leukemia advance online publication, 10 March 2015; doi:10.1038/leu.2015.38.
| Item Type: | Article |
|---|---|
| Subjects: | WH Haemic and lymphatic systems. Haematology |
| Divisions: | Planned IP Care > Oncology and Clinical Haematology |
| Related URLs: | |
| Depositing User: | Mrs Adele Creak |
| Date Deposited: | 30 May 2015 08:13 |
| Last Modified: | 30 May 2015 08:13 |
| URI: | http://www.repository.uhblibrary.co.uk/id/eprint/877 |
Actions (login required)
 |
View Item |
